Just a few months after dumping its lead asset and cutting its workforce in half, Cargo Therapeutics is jettisoning even more ...

Empress Therapeutics is halving its team, letting go of 23 employees as the biotech works to get its small-molecule science ...

As other gene editing programs fold or get sold, Arbor Biotechnologies has secured $73.9 million to advance its lead ...

After serving as the director of the National Human Genome Research Institute (NHGRI) for more than 15 years, Eric Green, M.D ...

HC Bioscience is shutting down after conducting preclinical models for a transfer RNA (tRNA) asset designed to treat ...

Vincerx Pharma has found a fast fix for the uncertainty over its future. | Vincerx Pharma has found a fast fix for the ...

Quest Diagnostics announced it is teaming up with Google Cloud to develop artificial intelligence programs that can ...

A year to the day after declaring the FDA’s clearance of its automated insulin pump, Sequel Med Tech announced that its first connected continuous glucose monitor will be Abbott’s FreeSty | Greenlit ...

After raising an impressive 1.2 billion euros in 2024, European venture capital firm Sofinnova Partners is topping up its ...

Having recently trimmed back its pipeline to a sole cancer candidate, Pyxis Oncology has now reduced its head count to match. | Having recently trimmed back its pipeline to a sole cancer candidate, ...

We hoped industry layoffs would relent in 2024. That's not what happened. Overall, biopharma layoffs rose 3% last year compared to 2023, according to an analysis of yearly data. So, here we are ...

J&J will now pick up almost the full tab for the phase 3 trial, and in return Nanobiotix will see the potential milestone payments that could come its way drop $105 million to $2.6 billion. Shares in ...